

**Table SI. Univariable regression models**

Variable	n	Effect estimate (95% CI)	p-value	Adj. R <sup>2</sup>
Impact score (scale 0–10)	218	0.264 (0.230–0.298)	<b>0.000</b>	0.513
DLQI	267	0.115 (0.091–0.139)	<b>0.000</b>	0.251
SAVES (BSA) score	272	0.039 (0.026–0.052)	<b>0.000</b>	0.107
Extent of vitiligo on the hands	271	0.726 (0.468–0.984)	<b>0.000</b>	0.099
Number of locations involved	275	0.094 (0.060–0.128)	<b>0.000</b>	0.095
Presence of vitiligo on the hands	271	0.607 (0.338–0.875)	<b>0.000</b>	0.065
Extent of vitiligo on the face	271	0.320 (0.176–0.464)	<b>0.000</b>	0.063
Number of active locations	191	0.104 (0.043–0.165)	<b>0.001</b>	0.051
Disease duration	263	0.002 (0.001–0.003)	<b>0.001</b>	0.036
Disease activity in past 6 months	191	0.401 (0.103–0.700)	<b>0.009</b>	0.031
Skin type*	278	0.193 (0.038–0.348)	<b>0.015</b>	0.018
Age at inclusion, years	291	0.010 (0.002–0.018)	<b>0.020</b>	0.015
Sex (F/M)	291	0.209 (–0.026–0.445)	0.082	0.007
Presence of vitiligo on the face	271	–0.100 (–0.448–0.249)	0.574	–0.003
Associated thyroid disease	258	0.085 (–0.301–0.471)	0.663	–0.003
Age of onset, years	266	–0.002 (–0.011–0.007)	0.694	–0.003

**Bold:**  $p < 0.05$ .

F: female; M: male; 95% CI: 95% confidence interval; SAVES: Self-Assessment Vitiligo Score; BSA: body surface area; DLQI: Dermatology Life Quality Index (For DLQI score: if questions were left unanswered these questions were scored 0. In case the questionnaire was considered not to be finalized by the patient (e.g. half of all questions left unanswered) the total DLQI score was not used).

\*Fitzpatrick skin types I–VI (assessed by patient or physician).